Marinus Pharmaceuticals
Radnor, US · Delaware corporation · 8 known investors
Founders & leadership
SB
Scott Braunstein, MDExecutive
EF
Edward F. SmithExecutive
JH
Joe Hulihan, MDExecutive
Board
NV
Nicole VitulloBoard director
EJ
Enrique J. Carrazana, MDBoard director
MR
Michael R. DoughertyBoard director
SH
Seth H.Z. FischerBoard director
TM
Tim M. MaylebenBoard director
EE
Elan EzicksonBoard director
Investors · 8
Avoro Capital AdvisorsNew York
Bain Capital Life SciencesBoston
Canaan PartnersStamford · $500K – $20M
Connecticut InnovationsNew Haven · $500K – $2M
Sofinnova VenturesMenlo Park · $100K – $15M
Domain AssociatesreportedPrinceton · $200K – $15M
Flare Capital PartnersreportedBoston · $1M – $10M
FOUNDATION MEDICAL PARTNERSreportedBoston
Reported raises · per SEC filings
Form D private placements$31.2M disclosed across 2 rounds · 2019–2022
▶$1.2MraisedApr 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedApr 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tim M. MaylebenDirector
- Nicole VitulloDirector
- Michael R. DoughertyDirector
- Charles AustinDirector
- Steven E. PfanstielExecutive Officer
- Saraswathy Nochur, Ph.D.Director
- Elan EzicksonDirector
- Martha Manning, Esq.Executive Officer
- Joseph Hulihan, M.D.Executive Officer
- Scott Braunstein, M.D.Executive Officer, Director
- Santiago Arroyo, M.D., Ph.D.Director
- Seth H.Z. FischerDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedDec 2019 · 4 investors · PharmaceuticalsRule 506(b)
▶$30MraisedDec 2019 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott Braunstein, MDExecutive Officer, Director
- Enrique J. Carrazana, MDDirector
- Michael R. DoughertyDirector
- Seth H.Z. FischerDirector
- Tim M. MaylebenDirector
- Nicole VitulloDirector
- Elan EzicksonDirector
- Edward F. SmithExecutive Officer
- Joe Hulihan, MDExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- Minimum investment
- $4.6M
- Sales commissions
- $1.8M
- Placement agents
- Oppenheimer & Co., Inc, Ladenburg Thalmann & Co. Inc., Craig-Hallum Capital Group LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
StockTwits5 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Perplexity4 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with Marinus Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who are Marinus Pharmaceuticals's investors?
- Marinus Pharmaceuticals's investors include Avoro Capital Advisors, Bain Capital Life Sciences, Canaan Partners, Connecticut Innovations, Sofinnova Ventures, Domain Associates, Flare Capital Partners, FOUNDATION MEDICAL PARTNERS.
- How much funding has Marinus Pharmaceuticals raised?
- Marinus Pharmaceuticals has disclosed $31.2M raised across 2 rounds.
- Where is Marinus Pharmaceuticals headquartered?
- Marinus Pharmaceuticals is headquartered in Radnor, US.